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Poster Session-II 117was 51 (range, 18–67) y., with 46 (54%) female donors, 33 (39%)
myeloid malignancies, 49 (58%) lymphoid malignancies, and 3
cases of SAA. The stem cell source was PBSC in 66 (78%) pa-
tients, while BM was used in 19 (22%) patients. 37 (43.5%)
were transplanted from a matched related donor, and 48
(56.5%) from a matched unrelated donor. A myeloablative condi-
tioning regimen was used in 24 (28%) patients, and 61 (72%) re-
ceived a reduced intensity regimen. The median concentrations of
CsA in the blood at 1, 2, 3 and 4 weeks after allo-SCT were 348
(range, 172–733), 284 (range, 137–535), 274 (range, 107–649), and
247 (37–695) ng/mL respectively. All patients engrafted at a me-
dian of 17 (range, 0–42) days after allo-SCT. With a median fol-
low-up of 16 (range, 5–29) months, grade 2–4 acute GVHD
occurred in 36 patients (42%) at a median of 29 (range, 6–100)
days after allo-SCT. The incidence of severe grade 3–4 acute
GVHD was 23% (95%CI, 14–32%). In multivariate analysis, we
found that higher whole-blood CsA concentration in the first
week following graft infusion, and before onset of acute GVHD
was the strongest parameter significantly associated with a reduced
the risk of severe grade 3–4 acute GVHD (P 5 0.01; RR 5 0.24;
95%CI, 0.08–0.73). This data indicates a close relationship be-
tween CsA trough blood concentration during the early post
allo-SCT period and the severity of acute GVHD. Inadequate
or insufficient early exposures to CsA can be a serious risk for de-
veloping severe acute GVHD. Therefore, precise monitoring of
CsA concentrations and achievement of a high CsA target concen-
tration may be an effective tool to prevent the onset of severe
acute GVHD.326
INFERIOR OUTCOME WITH ADDITION OF RITUXIMAB FOR ALLOGENEIC
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN ACUTE LYM-
PHOBLASTIC LEUKEMIA (ALL)
Kebriaei, P.1, Munsell, M.2, Gutierrez, K.1, de Lima, M.1, Giralt, S.1,
Hosing, C.1, Popat, U.1, Qazilbash, M.H.1, Thomas, D.3,
Kantarjian, H.3, Khouri, I.F.1, Champlin, R.E.1 1 University of Texas
M.D. Anderson Cancer Center, Houston, TX; 2 University of Texas
M.D. Anderson Cancer Center, Houston, TX; 3 University of Texas
M.D. Anderson Cancer Center, Houston, TX
We previously reported that rituximab was associated with a re-
duced incidence of acute graft versus host disease (GVHD) when in-
corporated into a standard transplant preparative regimen for ALL.
To confirm our findings, we conducted a randomized, prospective
study.
Methods: Adult ALL pts received a standard myeloablative con-
ditioning regimen of total body irradiation (TBI, 12 Gy in four daily
fractions) followed by etoposide 60 mg/kg  1 dose with allogeneic
HSCT. Rituximab was administered at 375 mg/m2 on days27,21,
17 and 114 following stem cell infusion in pts randomized to re-
ceive the drug. GVHD prophylaxis consisted of tacrolimus and
mini-dose methotrexate for all pts, and anti-thymocyte-globulin
was added to matched unrelated pts. Palifermin to reduce the inci-
dence of mucositis was administered to all pts. The first 20 pts
were randomized equally to the possibility of receiving rituximab,
with subsequent randomization based on a Bayesian adaptive algo-
rithm.
Results: Twenty-one pts have been entered onto study. Patient
characteristics and treatment outcomes are detailed in Table 1. Of
note, there were greater numbers of pts with disease beyond CR1
in the rituximab group. There was no significant difference between
the 2 treatment groups with respect to the incidence of acute
GVHD; 3 pts in the rituximab group developed chronic extensive
GVHD. Seven of 10 (70%) pts on the rituximab treatment arm
have died with a median time to death of 6.9 months: relapse n 5
4, infection n 5 2, organ failure n 5 1; no pts on the standard treat-
ment arm have died with a median follow-up of 14 months (range
3–32 months). Overall survival for the rituximab group was signifi-
cantly worse at 30% versus 100% for the standard treatment arm,
p 5 0.005. Four of 10 (40%) pts on the rituximab treatment arm
have had progressive disease, and all 4 of these pts died. Only 1 of
11 (9%) pts on the standard treatment arm had progressive disease
at 14.5 months after HSCT and remains alive at 17.6 months after
HSCT. In conclusion, our results demonstrate that the addition ofrituximab to the standard etoposide and TBI conditioning regimen
for allogeneic HSCT in ALL does not impact GVHD. Furthermore,
rituximab appears to negatively impact survival, with increased risk
of disease relapse. However, the small sample size and greater num-
bers of pts with advanced disease in the rituximab arm limit these
conclusions.
Table 1. Patient Characteristics and Treatment Results
Etoposide/ Etoposide/
TBI TBI/RituximabNo. pts No. ptsTotal Treated 11 10
Median Recipient
Age in Years (range)33 (20247) 32 (19252) 0.382Gender (%): 0.999
Female 3 (27) 3 (30)
Male 8 (73) 7 (70)
Diagnosis Status (%) 0.158
CR1 7 (64) 3 (30)
CR2 4 (36) 3 (30)
Beyond CR2 0 (0) 1 (10)
Relapse 0 (0) 3 (30)
Histology (%): 0.035
T-cell 0 (0) 4 (40)
B-cell 11 (100) 6 (60)
Ph1 (%) 0.311
No 7 (64) 9 (90)
Yes 4 (36) 1 (10)
Donor Type (%) 0.387
Matched related 6 (55) 3 (30)
Matched unrelated 5 (45) 7 (70)
Stem Cell Source (%)* 0.008
Bone marrow 3 (27) 9 (90)
Peripheral blood 8 (73) 1 (10)
Acute GVHD (%) 0.999
Grades II-IV 3 (27) 9 (90)
Grades III-IV 0 0
Chronic Extensive GVHD (%) 0 3 (33) 0.090
Overall Survival 100% 30% 0.005
Progression-Free Survival 90% 60% 0.009327
DEFECTIVE IMMUNE SYNAPSE FORMATION OF UMBILICAL CORD
BLOOD-DERIVED NATURAL KILLER CELL S IS ABROGATED BY
EX VIVO EXPANSION
Xing, D.1, Ramsay, A.G.2, Gribben, J.G.2, Decker, W.K.1, Li, S.1,
Robinson, S.N.1, Yang, H.1, David, S.1, Hosing, C.M.1,
Elizabeth, S.J.1, Zweidler-McKay, P.A.1, Bollard, C.M.3 1 Universityof
Texas MD Anderson Cancer Center, Houston, TX; 2 Institue of Cancer
Barts and the London School of Medicine, London, United Kingdom; 3 Bay-
lor College of Medicine, Hosuton, TX
Activated natural killer (NK) cells derived from cord blood (CB)
have been reported to mediate a significant graft versus leukemia ef-
fect (GVL). However unmanipulated CB NK cells exhibit poor cy-
tolytic activity against tumor cells in vitro, thus limiting their
clinical application. We investigated the mechanism for the poor
cytolytic activity of CB NK cells and whether the defect can be
overcome with ex vivo expansion. NK cell killing of the tumor tar-
get cells is achieved by the formation of a mature immune synapse,
followed by secretion of lytic granules containing perforin and
granzymes. We hypothesized that CB NK cells exhibit low cytotox-
icity against leukemia blasts due to a defect in the formation of the
immune synapse. We have found reduced ability of CB NK cells to
form immune synapses with leukemia target cells contributing to
the decreased cytotoxicity of unmanipulated CB NK cells com-
pared to adult peripheral blood (APB) NK cells. F-actin polariza-
tion was observed in a mean of 12% (range 9–21%) of the CB
NK cell/tumor cell conjugates versus a mean of 85% (range 68–
87) of APB NK/tumor conjugates (p\ 0.001). This impairment
could then be reversed by ex vivo expansion of CB NK cells with
118 Poster Session-IIIL-2. IL-2-expanded CB NK cells formed increased immune syn-
apses with K562 tumor cells (mean 65%; 60–71%) and primary hu-
man AML blasts (mean 48%, range 39–55%), comparable to the
levels generated with peripheral blood NK cells. Additionally, we
demonstrated that ex vivo expanded CB NK cells could efficiently
kill human AML engrafted in a NOD/scid/IL-2Rg-null mouse
model. A mean 50% (37–66%) reduction in AML blasts was
observed in comparison to control groups (mean 3%;range 2.4–
4.7%) by 6 weeks post NK infusion (p\0.05). Our results suggest
that ex vivo expansion of CB NK cells is a feasible and effective
strategy for the treatment of AML.328
CHARACTERIZATION OF CTL CLONES ISOLATED FROM BONE MARROW
TRANSPLANT RECIPIENT WITH HLA-CW-MISMATCHED DONOR
Murata, M., Sugimoto, K., Terakura, S., Naoe, T. Nagoya University
Graduate School of Medicine, Nagoya, Aichi, Japan
HLA-Cw disparity in a donor increases the risk of severe acute
GVHD after BMT. However, HLA-Cw-specific cytotoxic T lym-
phocytes (CTLs) generated in post-transplant recipients who de-
velop acute GVHD have not been characterized in detail. Here,
we characterized CTL clones isolated from a recipient at the on-
set of grade II acute GVHD who was transplanted from an HLA-
A, B and DRB1-matched, Cw-mismatched (recipient, Cw*0303/
Cw*0702; donor, Cw*0801/Cw*0702) unrelated donor. Seven
CTLs were isolated. Four CTLs were CD8-positive, one was
CD4-positive, and two were CD4/CD8-double positive. Three
of those including a CD8-positive CTL, a CD4-positive CTL
and a CD4/CD8-double positive CTL had exactly the same nu-
cleotide sequences in the CDR3 region of their T cell receptors,
suggesting these three CTLs with variable phenotypes originated
from a single clone. All CTLs lysed Epstein Barr virus-trans-
formed lymphoblastoid cell (B-LCL) from the recipient and donor
B-LCL transfected with the HLA-Cw*0303 cDNA construct, but
failed to lyse B-LCL from the donor. COS cells transfected with
HLA-Cw*0303 cDNA construct stimulated IFNg production by
all CTLs. Thus, all isolated CTLs recognized HLA-Cw*0303
molecule as an alloantigen. COS cells transfected with Cw*0303
mutants in which amino acids constituting peptide-binding
pockets (aa position: 114, 116, 152, or 163) were substituted
with Cw*0801-amino acids could not stimulate IFNg production
by any CTLs, whereas COS cells transfected with Cw*0303 mu-
tants bearing Cw*0801-amino acids outside the positions consti-
tuting peptide-binding pockets stimulated all CTLs as well as
the wild-type Cw*0303 construct. These data indicated that pep-
tides bound to Cw*0303 molecules influence the allorecognition
of Cw*0303-specific CTLs. Taken together, our findings suggest,
although the immunogenicity of HLA-Cw antigens is considered
to be low as a consequence of their low level of cell surface ex-
pression, HLA-Cw-specific CTL clones with a variable phenotype
can naturally arise in post-transplant recipients and cause acute
GVHD through recognition of the peptides bound to Cw mole-
cules. This is consistent with a recent statistical study showing
a significant association between some specific amino acid substi-
tutions at positions constituting peptide-binding pockets of the
HLA-Cw molecule and the occurrence of severe acute GVHD
after unrelated BMT.329
A ROLE FOR NF-KB INDUCING KINASE (NIK) IN GRAFT VERSUS HOST RE-
ACTIONS
Sanchez-Valdepenas, C.2, Casanova, L.1, Colmenero, I.3, Gonzalez-
Vicent, M.1, Madero, L.1, Diaz, M.A.1, Fresno, M.2, Ramirez, M.1 1 Hos-
pital Universitario Nin˜o Jesus, Madrid, Spain; 2 Centro de Biologıa Molec-
ular, Madrid, Spain; 3 Hospital Universitario Nin˜o Jesus, Madrid, Spain
NF-KB is a family of transcription factors with an important role
in immune and inflammatory responses, and represents a target for
the treatment of immune diseases. NF-KB inducing kinase (NIK) is
required for the activation of the NF-KB noncanonical (or alterna-
tive) pathway. We have studied the role of NIK in graft versus hostdisease (GVHD) in humans and in a murine model of GVHD.
Human T lymphocytes activated in vitro (CD3 1 CD28 anti-
bodies, and/or TNF-a) showed an initial downregulation of
NIK, followed by an increase above basal levels, during the first
48 hours. On the other hand, circulating T lymphocytes from pa-
tients with acute GVHD (aGVHD) expressed NIK while T cells
from healthy donors did not, and T lymphocytes infiltrating the
dermis of pathological lesions of those patients expressed high level
of NIK. We next explored the effects of suppressing NIK in a mu-
rine model of GVHD in mice: H2Db T lymphocytes transplanted
into fully mismatched H2Dd recipients. Donor mice were either
aly/aly (NIK deficient) or C57BL/6 (control), and recipient mice
were Balb/c. Mice recipient of BL6 cells developed a severe form
of aGVHD and died in the third week after transplant. On the con-
trary, mice transplanted with aly T lymphocytes survived for 3
months and did not develop GVHD Histopathological analysis of
skin, gut and liver of these surviving mice showed no sign of
GVHD. We next studied the fate of the infused T lymphocytes
in the early days postransplant, in order to ascertain the cause of
the difference in GVHD survival. We found that aly and BL6 T
lymphocytes had the same capacity for homing into the spleens,
but the clonal expansion of aly T lymphocytes was significantly im-
paired at day 5. Analysis of in vivo T cell divisions showed the same
kinetics for aly and BL6 T lymphocytes at 1, 3 and 5 days after
transplant. Therefore, aly T cells divided in vivo but the process
was not productive. Finally, the proportions of apoptotic aly T lym-
phocytes were higher than those of BL6, at days 1 and 3, but not at
day 5. We also detected lower amounts of Th1 cytokines levels in
the serum of mice receiving aly vs. BL6 T cells, 5 days after trans-
plant. In summary, NIK-deficient T lymphocytes had a normal
proliferative capacity but an increased apoptotic rate early after
transplant compared to controls, and were unable of mounting
a successful GVH reaction in the fully mismatched allogeneic
setting.330
PLASMA CYTOKINE LEVELS DISTINGUISH CHRONIC GRAFT VERSUS
HOST DISEASE (CGVHD) SYMPTOM PROFILE GROUPS
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Mooney, K.H.2, Rehman, N.K.3, Dickinson, J.5, Palit, P.1, Beck, S.L.2,
Kline Leidy, N.6, Cole, M.L.7, Dudley, W.N.2, Gress, R.E.3,
Pavletic, S.Z.3 1 National Institutes of Health, Bethesda, MD; 2 University
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Background:Understanding the biologic milieu associated with
differing symptom profiles in allogeneic HSCT survivors with
cGVHD has the potential to clarify the pathogenesis of cGVHD
activity and tissue damage, and may direct the development of
new strategies to ameliorate symptoms and improve quality of
life.
Objective: To determine if differing cGVHD symptom profiles
are associated with unique patterns of pro-inflammatory cytokine ex-
pression and markers of systemic immune activation.
Methods: Plasma levels of sBAFF, IL-1b, IL-1 receptor antago-
nist, IL-6, soluble IL-6 receptor, soluble TNF-receptor II, MCP-
1, and MIG were assayed by sandwich ELISA. Lymphocyte subset
quantities were measured. Concurrently, the Lee Chronic GVHD
Symptom Scale, a self-report measure of cGVHD symptoms, and
clinical data were obtained. Data from 79 patients were analyzed us-
ing descriptive statistics, latent profile analysis, and multinomial lo-
gistic regression.
Results: Three distinct symptom subgroups were identified
through latent profile analysis: Group 1 (low on all symptoms),
Group 2 (prominent oral, upper GI, and weight loss symptoms);
and Group 3 (eye, muscle/joint, fatigue and mood symptoms). Mul-
tinomial logistic regression, controlling for age, length of time since
transplant, cGVHD severity, intensity of immunosuppression and
post-transplant lymphocyte reconstitution, revealed that IL-6,
TNF-RII, MCP-1 and sBAFF levels significantly distinguished the
three symptom subgroups.
